M Coto and S Pérez-del-Pulgar contributed equally to this study and both should be considered first authors.
Donor and Recipient IL28B Polymorphisms in HCV-Infected Patients Undergoing Antiviral Therapy before and after Liver Transplantation
Article first published online: 5 APR 2011
©2011 The Authors Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 11, Issue 5, pages 1051–1057, May 2011
How to Cite
Coto-Llerena, M., Pérez-del-Pulgar, S., Crespo, G., Carrión, J. A., Martínez, S. M., Sánchez-Tapias, J. M., Martorell, J., Navasa, M. and Forns, X. (2011), Donor and Recipient IL28B Polymorphisms in HCV-Infected Patients Undergoing Antiviral Therapy before and after Liver Transplantation. American Journal of Transplantation, 11: 1051–1057. doi: 10.1111/j.1600-6143.2011.03491.x
- Issue published online: 26 APR 2011
- Article first published online: 5 APR 2011
- Received 19 August 2010, revised 10 December 2010 and accepted for publication 08 January 2011
- interferon treatment;
- liver transplantation;
- virological response;
- waiting list
IL28B gene polymorphisms are associated with the response to antiviral therapy in hepatitis C patients. We investigated the influence of IL28B polymorphisms on the response to therapy before and after liver transplantation (LT). Genotyping of SNPs rs8099917 and rs12979860 was performed in 128 HCV-infected liver transplant recipients and in their donors; all patients underwent antiviral treatment after LT. The prevalence of genotypes rs12979860CC and rs8099917TT was higher in donors than in recipients (50% vs.19%, p < 0.001 and 67% vs. 38%, p < 0.001, respectively). Response to antiviral therapy was significantly higher for recipient genotype rs12979860CC as compared to rs12979860CT/TT both before (100% vs. 48% p = 0.013) and after LT (59% vs. 25% p = 0.002). The figures were almost identical for SNP rs8099917. Sustained virological response after LT was particularly high in patients with favorable recipient and donor genotypes (p < 0.01 for both SNPs). In a subgroup of 34 patients treated while awaiting LT, a favorable donor IL28B genotype was associated with an improved virological response after LT. Our results support a major role of recipient IL28B genotype in the response to antiviral treatment for hepatitis C recurrence. Interestingly, donor genotype also seems to influence the response pattern, especially in recipients who have a favorable IL28B genotype.